目次

TABLE OF CONTENT

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 PRIMARY SOURCES
2.1.2.2 KEY INDUSTRY INSIGHTS
2.1.2.3 BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 REVENUE-MAPPING BASED MARKET ESTIMATION
2.2.2 END USER BASED MARKET ESTIMATION
2.2.3 MARKET FORECASTING APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RECESSION IMPACT ASSESMENT APPROACH
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 MAJOR DRIVERS
5.2.2 KEY RESTRAINTS
5.2.3 KEY GROWTH OPPORTUNITIES
5.2.4 INDUSTRY-SPECIFIC CHALLENGES
5.3 PORTER’S FIVE FORCES ANALYSIS
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.4.2 REGULATORY TRENDS, BY REGION
5.5 ECOSYSTEM MARKET MAP
5.6 VALUE CHAIN ANALYSIS
5.7 SUPPLY CHAIN ANALYSIS
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.8.2 AVERAGE SELLING PRICE TREND, BY REGION
5.9 PATENT ANALYSIS
5.10 TRADE ANALYSIS
5.11 TECHNOLOGY ANALYSIS
5.11.1 KEY TECHNOLOGY
5.11.1.1 MALDI- TOF MASS SPECTROMETRY
5.11.2 COMPLEMENTARY TECHNOLOGY
5.11.2.1 OPTICAL IMMUNOSENSORS
5.11.2.1 ELECTROCHEMICAL IMMUNOSENSORS
5.11.3 ADJACENT TECHNOLOGY
5.11.3.1 AUTOMATED MULTIPLEX PCR SYSTEMS
5.12 KEY CONFERENCES & EVENTS IN 2024-2025
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA
5.15 CASE STUDY ANALYSIS
5.16 UNMET NEEDS/END USER EXPECTATIONS IN CLINICAL MICROBIOLOGY MARKET
5.17 ADJACENT MARKET ANALYSIS
5.18 INVESTMENT AND FUNDING SCENARIO

6 MICROBIOLOGY TESTING MARKET, BY END USE APPLICATION (USD MILLION; 2022—2029)
6.1 INTRODUCTION
6.2 CLINICAL DISEASE DIAGNOSIS
6.3 FOOD AND BEVERAGE TESTING
6.4 PHARMA AND BIOPHARMA TESTING
6.5 ENVIRONMENTAL TESTING
6.6 CHEMICAL AND MATERIAL MANUFACTURING
6.7 OIL AND GAS TESTING

7 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT (USD MILLION; 2022—2029)
7.1 INTRODUCTION
7.2 INSTRUMENTS
7.2.1 LABORATORY INSTRUMENTS
7.2.1.1 INCUBATORS
7.2.1.2 GRAM STAINERS
7.2.1.3 BACTERIAL COLONY COUNTERS
7.2.1.4 AUTOCLAVE STERLIZERS
7.2.1.5 MICROBIAL AIR SAMPLERS
7.2.1.6 BLOOD CULTURE SYSTEMS
7.2.1.7 ANAEROBIC CULTURE SYSTEMS
7.2.1.8 MICROBIAL CULTURE SYSTEMS
7.2.1.9 PETRI DISH FILLERS
7.2.1.10 OTHER LABORATORY INSTRUMENTS
7.2.2 MICROBIOLOGY ANALYZERS
7.2.2.1 MOLECULAR DIAGNOSTIC INSTRUMENTS
7.2.2.2 MASS SPECTROMETERS
7.2.2.3 MICROSCOPES
7.3 REAGENTS AND CONSUMABLES
7.3.1 PATHOGEN SPECIFIC KITS
7.3.2 GENERAL REAGENTS

8 CLINICAL MICROBIOLOGY MARKET, BY DISEASE (USD MILLION; 2022—2029)
8.1 INTRODUCTION
8.2 RESPIRATORY DISEASE
8.3 BLOODSTREAM INFECTIONS
8.4 GASTROINTESTINAL DISEASE
8.5 SEXUALLY TRASMITTED DISEASE
8.6 URINARY TRACT INFECTIONS
8.7 PERIODONTAL DISEASE
8.8 OTHER DISEASE
8.9 CULTURE MEDIA AND SERA

9 CLINICAL MICROBIOLOGY MARKET, BY END USER (USD MILLION; 2022—2029)
9.1 INTRODUCTION
9.2 HOSPITALS AND DIAGNOSTICS CENTERS
9.3 CONTRACT TESTING LABORATORIES
9.4 RESEARCH AND ACADEMIC INSTITUTES

10 HEALTHCARE ANALYTICAL TESTING MARKET, BY REGION (USD MILLION; 2022—2029)
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA: RECESSION IMPACT
10.2.1 US
10.2.3 CANADA
10.3 EUROPE
10.3.1 EUROPE:RECESSION IMPACT
10.3.2 GERMANY
10.3.3 FRANCE
10.3.4 UK
10.3.5 ITALY
10.3.6 SWITZERLAND
10.3.7 SPAIN
10.3.8 REST OF EUROPE (ROE)
10.4 ASIA PACIFIC (APAC)
10.4.1 ASIA PACIFIC: RECESSION IMPACT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA
10.4.6 SOUTH KOREA
10.4.7 REST OF ASIA PACIFIC (ROAPAC)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
10.5.2 BRAZIL
10.5.3 MEXICO
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MIDDLE EAST AND AFRICA: RECESSION IMPACT
10.6.2 GCC REGION
10.6.3 REST OF MIDDLE EAST AND AFRICA

11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN (2021-2024)
11.3 REVENUE ANALYSIS
11.4 MARKET SHARE ANALYSIS BY KEY PLAYERS, 2023
11.4.1 CLINICAL MICROBIOLOGY MARKET
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 COMPANY FOOTPRINT
11.5.5.2 REGION FOOTPRINT
11.5.5.3 PRODUCT FOOTPRINT
11.5.5.4 END USER FOOTPRINT
11.5.5.4 END USE APPLICATION FOOTPRINT
11.6 COMPANY EVALUATION MATRIX:START-UP/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.6.5.1 DETAILED LIST OF KEY STARTUPS/SMES
11.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7 C0OMPETITIVE SITUATION AND TRENDS (2021-2024)
11.7.1 NEW PRODUCT LAUNCHES & APPROVALS
11.7.2 DEALS
11.7.3 OTHER DEVELOPMENTS
11.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
11.9 R&D ASSESSMENT OF KEY PLAYERS PRODUCT COMPARISON
11.1 COMPANY VALUATION AND FINANCIAL METRICS

12 COMPANY PROFILES
(Business Overview, Product mapping, and key features, Industry-specific Developments for 2020-2024)
12.1 KEY PLAYERS
12.1.1 BIO-RAD LABORATORIES INC.
12.1.2 ABBOTT LABORATORIES
12.1.3 BRUKER CORPORATION
12.1.4 BECTON DICKINSON AND COMPANY.
12.1.5 F. HOFFMANN-LA ROCHE LTD.
12.1.6 HOLOGIC CORPORATION
12.1.7 DANAHER CORPORATION (CEPHEID INC.)
12.1.8 BIOMERIEUX SA
12.1.9 THERMO FISHER SCIENTIFIC INC.
12.1.10 AGILENT TECHNOLOGIES INC.
12.1.11 MERCK KGAA
12.1.12 SHIMADZU CORPORATION
12.1.13 NEOGEN CORPORATION.
12.1.14 CHARLES RIVER LABORATORIES
12.1.15 ABBOTT LABORATORIES
12.1.16 BIOGEN
12.1.17 ABBVIE
12.2 OTHER COMPANIES
12.2.1 MODERNA.
12.2.2 NOVO NORDISK
12.2.3 REGENERON
12.2.4 ILLUMINA
12.2.5 BIO-TECHNE CORPORATION
12.2.6 QIAGEN N.V.
12.2.7 PACIFIC BIOSCIENCES OF CALIFORNIA, INC..
12.2.8 OXFORD IMMUNOTEC GLOBAL PLC

13 APPENDIX
13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 CUSTOMIZATION OPTIONS
13.5 RELATED REPORTS
13.6 AUTHOR DETAILS